Bruker has launched its neofleX Imaging Profiler MALDI-TOF/TOF for mass spectrometry imaging (MSI) applications.

Suitable for mass spectrometry-based tissue imaging, Bruker states that the device addresses the unmet needs of moving from discovery imaging to translational and clinical tissue research.

NeofleX is also compatible with the MALDI-ISH method announced at ASMS 2024 by AmberGen.

MALDI-ISH multiplexes imaging of up to 12 oligomers of interest (RNA/DNA) for multi-omic spatial tissue research in neuroscience, infectious disease, and oncology.

In addition, the company says the neofleX excels at providing more insight per pixel through multi-omic spatial biology data from tissue sections that can positively correlate targeted proteins with glycans, metabolites, lipids, endogenous peptides, xenobiotics, and now RNA/DNA.

The neofleX is compatible with existing Bruker software and hardware, including its MALDI Imaging software and consumables ecosystems such as IntelliSlides and SCiLSautopilot – tools intended to simplify sample tracking, preparation, and analysis and to automate mass-spec imaging runs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Dr Michael Easterling, vice president of MSI for Bruker’s life sciences mass spectrometry division, the device’s multimodal software and workflows on the benchtop will support a range of biopharma and clinical research tasks.

Easterling said: “NeofleX brings novel capabilities to spatial biology, including spatial proteomics combined with unique multiomics correlations for developing actionable biological insights.”

The device’s launch follows Bruker’s recent acquisition of ELITechGroup for $942m.

Last year, Bruker entered a partnership with Advanced Diagnostics to validate the use of the company’s respective Arc and MALDI Biotyper systems.